NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%
NIFTY23,4060.33%
SENSEX74,3460.41%
BANKNIFTY54,1860.88%
NIFTY IT29,3845.57%
PHARMA24,0870.33%
AUTO26,0930.05%
FMCG48,1241.01%
METAL13,5350.17%
REALTY762.601.39%
ENERGY40,1970.02%

Narayana Hrudayalaya Reports Strong EBITDA Growth, Maintains Aggressive Capex Plan

Narayana Hrudayalaya (NARH) has posted a strong EBITDA of INR5.1 billion for the quarter, representing a 43% year-over-year (YoY) growth. This performance is attributed to the robust performance of both India and Cayman operations, as well as the consolidation of the UK subsidiary. The company's EBITDA has exceeded its projected levels by 7%.

The management has reaffirmed its plans to invest in capital expenditures (capex) and to grow throughput over the next three to four years through debottlenecking, refurbishment, and improved bed mix. In the medium term, Narayana Hrudayalaya intends to add approximately 1,535 beds over the next three years through greenfield and brownfield expansion across Bengaluru, Kolkata, and Raipur.

Revised EBITDA Projections

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

YearFY27E EBITDAFY28E EBITDA
CurrentIncrease by 2%Increase by 3%

Maintaining its 'BUY' rating, Prabhudas Lilladher has revised its target price for Narayana Hrudayalaya to INR2,250 per share, based on an estimated earnings multiple of 23 times (EV/EBITDA) for the India business and 15 times (EV/EBITDA) for international operations, both calculated for the fiscal year 2028 (FY28E).

Investor Takeaway

Investors should consider buying Narayana Hrudayalaya with a price target of Rs 2250.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
[email protected].

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.